Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: Results of a phase II trial

Journal of Thoracic Oncology

Volumn 3, Issue 11, 2008, Pages 1308-1316

  Socinski, Mark A ^a   Raju, Robert N ^b   Neubauer, Marcus ^c   Smith, David A ^d   Richards, Donald A ^e   Savin, Michael ^f   Ruxer, Robert L ^f   Reynolds, Craig H ^g   Zhan, Feng ^g   Bromund, Jane L ^h   Chen, Ruqin ^h   Obasaju, Coleman ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Dayton Oncology and Hematology   (United States)

^c Kansas City Cancer Center   (United States)

^d Northwest Cancer Specialists   (United States)

^e Tyler Cancer Center   (United States)

^f TEXAS ONCOLOGY   (United States)

^g Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Folic acid; Pemetrexed; SCLC; Vitamin

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; THYMIDYLATE SYNTHASE; VITAMIN B COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; CANCER STAGING; COHORT ANALYSIS; DIET SUPPLEMENTATION; DRUG ANTAGONISM; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; THYMIDYLATE SYNTHASE; VITAMIN B COMPLEX;

EID: 58949083363     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181898e32     Document Type: Article

References (25)

1. American Cancer Society: Cancer Facts and Figures 2007. Available at: http://www.cancer.org/docroot/STT/content/STT-1x-cancer-Facts-Fig ures-2007.asp. Accessed August 17, 2007.
2. Navada S, Lai P, Schwartz AG, et al. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J Clin Oncol 2006;24(18S) abstract 7082.
3. Simon GR, Wagner H. Small-cell lung cancer. Chest 2003;123:259-271.
4. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
5. Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer: a systematic review. Program in evidence-based care, cancer Care Ontario 2006; evidence-based series #7-17: section 2.
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™, small cell lung cancer V1.2007. Available at: http://www.nccn.org/professionals/physician-gls/PDF/sclc.pdf. Accessed August 17, 2007.
7. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26(2 Suppl 6):42-47.
8. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26(2 Suppl 6):68-73.
9. Rusthoven JJ, Eisenhauer E, Butts C, et al. National cancer Institute of Canada Clinical Trials Group. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer (A phase II study). J Clin Oncol 1999;17:1194-1199.
10. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-741.
11. Smit EF, Mattson K, von LPawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer (A phase II study). Ann Oncol 2003;14:455-460.
12. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small- cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin (A multicenter phase II trial). Ann Oncol 2000;11:435-440.
13. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma (A study of the National cancer Institute of Canada Clinical Trials Group). Cancer 2001;92:595-600.
14. Koshy S, Herbst R, Obasaju C, et al. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:631 (abstract 7074).
15. Scagliotti G, Kortsik C, Castellano D, et al. Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:625 (abstract 2513).
16. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
17. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and ethylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
19. Leemis LM, Trivedi KS. A Comparison of Approximate Interval Estimators for the Bernoulli Parameter. Am Stat 1996;50:63-68.
20. Cancer Therapy Evaluation Program. Common toxicity criteria, Version 2.0. DCTD, NCI, NIH, DHHS. 1998.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or meta-static cancer. Clin Cancer Res 2007;13:2675-2683.
24. Hanna NH, Ansari R, Bhatia R, et al. Pemetrexed in patients (pts) with relapsed small cell lung Cancer (SCLC): a phase II study from the Hoosier Oncology Group. J Clin Oncol 2006;24(18S) abstract 7063.
25. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006;24:4840 - 4847. 26. Gillenwater HH, Socinski MA. Extensive-stage small cell lung cancer. In Detterbeck F, Rivera M, Socinski MA, (Eds.), Diagnosis and Treatment of Lung cancer: An Evidence-based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders, 2001. Pp. 360-376.